62 research outputs found
Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses
Full text linkMultiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
Get PDF
Recommended from our members
Reduction of risk of secondary progressive multiple sclerosis within two years of treatment with cladribine tablets: An analysis of the clarity study
No full textRecommended from our members
Cladribine Tablets 35 mg/kg Is Efficacious in Patients Aged Above and Below 45 Years with Relapsing Multiple Sclerosis in the Clarity Study
No full textReduction of risk of secondary progressive multiple sclerosis within two years of treatment with cladribine tablets: An analysis of the clarity study
No full textManagement of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines
No full textRecommended from our members
Efficacy of cladribine tablets 3.5 mg/kg in patients with relapsing multiple sclerosis aged above and below 45 years; clarity and clarity extension
No full text- …
